medigraphic.com
ISSN 0016-3813 (Print)

2016, Number 1

<< Back Next >>

Gac Med Mex 2016; 152 (1)

Biomarkers in high-grade gliomas: A systematic review

Manrique-Guzmán S

Language: Spanish
References: 46
Page: 87-93
PDF size: 90.75 Kb.


ABSTRACT

Background: Biomarkers are a subcategory of clinical signs that can be measured and reproduced with precision and influence to predict outcome. Tissue, cells, and fluid conform the biological process. Biomarker usefulness is to determine and specify illness predisposition counting with variability and validity. Process systematization can reduce operative costs. To date, four major biomarkers have been described for high-grade gliomas: 1p/19q deletion, O6-methylguanine-DNA methyltransferase (MGMT) promoter mutation, IDH1/IDH2 mutation, and microRNA. In this manuscript we present a systematic review according to the MOOSE protocol to establish the bases to describe the utility of biomarkers in high-grade tumors. Materials and methods: We conducted a systematic review of the literature according to the PRISMA and MOOSE guides of all the published data from January 2004 to November 2014 with the key words: “biological markers” and “glioblastoma” that included OR and 95% CI. One researcher performed data extraction and analysis. Results: A total of 169 articles were found in three major medical search engines: PubMed (42), Embase (30) and Ovid (96). Conclusion: Biomarkers are tools designed for early detection of specific illnesses such as high-grade glioma. Lack of methodological standardization slows down the speed of progress.


REFERENCES

  1. Mayeux R. Biomarkers: potential uses and limitations. NeuroRx. 2004;1(2):182-8.

  2. Strimbu K, Tavel JA. What are biomarkers? Curr Opin HIV AIDS. 2010;5(6):463-6.

  3. Naylor S. Biomarkers: current perspectives and future prospects. Expert Rev Mol Diagn. 2003;3(5):525-9.

  4. Pepe MS, Thompson ML. Combining diagnostic test results to increase accuracy. Biostatistics. 2000;1(2):123-40.

  5. Mikeska T, Craig JM. DNA methylation biomarkers: cancer and beyond. Genes. 2014;5(3):821-64.

  6. Floyd D, Purow B. Micro-masters of glioblastoma biology and therapy: increasingly recognized roles for microRNAs. Neuro Oncol. 2014;16(5):622-7.

  7. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med. 2009;151(4):W65-94.

  8. Masui K, Cloughesy TF, Mischel PS. Review: molecular pathology in adult high-grade gliomas: from molecular diagnostics to target therapies. Neuropathol Appl Neurobiol. 2012;38(3):271-91.

  9. Cohen AL, Colman H. Glioma biology and molecular markers. Cancer Treat Res. 2015;163:15-30.

  10. Zou P, Xu H, Chen P, et al. IDH1/IDH2 mutations define the prognosis and molecular profiles of patients with gliomas: a meta-analysis. PloS one. 2013;8(7):e68782.

  11. Parsons DW, Jones S, Zhang X, et al. An integrated genomic analysis of human glioblastoma multiforme. Science. 2008;321(5897):1807-12.

  12. Mulero-Navarro S, Esteller M. Epigenetic biomarkers for human cancer: the time is now. Crit Rev Oncol Hematol. 2008;68(1):1-11.

  13. Riemenschneider MJ, Hegi ME, Reifenberger G. MGMT promoter methylation in malignant gliomas. Target Oncol. 2010;5(3):161-5.

  14. Zhang W, Zhang J, Hoadley K, et al. miR-181d: a predictive glioblastoma biomarker that downregulates MGMT expression. Neuro Oncol. 2012;14(6):712-9.

  15. Ang C, Guiot MC, Ramanakumar AV, Roberge D, Kavan P. Clinical significance of molecular biomarkers in glioblastoma. Can J Neurol Sci. 2010;37(5):625-30.

  16. Castellanos-Rizaldos E, Milbury CA, Karatza E, Chen CC, Makrigiorgos GM, Merewood A. COLD-PCR amplification of bisulfite-converted DNA allows the enrichment and sequencing of rare un-methylated genomic regions. PloS one. 2014;9(4):e94103.

  17. Chen Y, Hu F, Zhou Y, Chen W, Shao H, Zhang Y. MGMT promoter methylation and glioblastoma prognosis: a systematic review and meta- analysis. Arch Med Res. 2013;44(4):281-90.

  18. Mathupala SP, Mittal S, Guthikonda M, Sloan AE. MicroRNA and brain tumors: a cause and a cure? DNA Cell Biol. 2007;26(5):301-10.

  19. Wang XF, Shi ZM, Wang XR, et al. MiR-181d acts as a tumor suppressor in glioma by targeting K-ras and Bcl-2. J Cancer Res Clin Oncol. 2012; 138(4):573-84.

  20. Xue J, Niu J, Wu J, Wu ZH. MicroRNAs in cancer therapeutic response: Friend and foe. World J Clin Oncol. 2014;5(4):730-43.

  21. Teplyuk NM, Mollenhauer B, Gabriely G, et al. MicroRNAs in cerebrospinal fluid identify glioblastoma and metastatic brain cancers and reflect disease activity. Neuro Oncol. 2012;14(6):689-700.

  22. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med. 2009;151(4):W65-94.

  23. Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000; 283(15):2008-12.

  24. Steels E, Paesmans M, Berghmans T, et al. Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis. Eur Respir J. 2001;18(4):705-19.

  25. Mizoguchi M, Guan Y, Yoshimoto K, et al. Clinical implications of microRNAs in human glioblastoma. Front Oncol. 2013;3:19.

  26. Weller M, Cloughesy T, Perry JR, Wick W. Standards of care for treatment of recurrent glioblastoma--are we there yet? Neuro Oncol. 2013; 15(1):4-27.

  27. Prickett TD, Samuels Y. Molecular pathways: dysregulated glutamatergic signaling pathways in cancer. Clin Cancer Res. 2012;18(16):4240-6.

  28. Weller M, Stupp R, Hegi M, Wick W. Individualized targeted therapy for glioblastoma: fact or fiction? Cancer J. 2012;18(1):40-4.

  29. Laperriere N, Weller M, Stupp R, et al. Optimal management of elderly patients with glioblastoma. Cancer Treat Rev. 2013;39(4):350-7.

  30. Parikh K, Peppelenbosch MP. Kinome profiling of clinical cancer specimens. Cancer Res. 2010;70(7):2575-8.

  31. Pedeboscq S, L’Azou B, Passagne I, et al. Anticancer drugs exert differential apoptotic and cytotoxic effects on glioblastoma primary cultures with various EGFR and bcl-2 profiles. J Exp Ther Oncol. 2009;8(2): 105-16.

  32. Jain RK, Duda DG, Willett CG, et al. Biomarkers of response and resistance to antiangiogenic therapy. Nat Rev Clin Oncol. 2009;6(6):327-38.

  33. Nano R, Capelli E, Facoetti A, Benericetti E. Immunobiological and experimental aspects of malignant astrocytoma. Anticancer Res. 2009;29(7): 2461-5.

  34. Chang SM, Lamborn KR, Kuhn JG, et al. Neurooncology clinical trial design for targeted therapies: lessons learned from the North American Brain Tumor Consortium. Neuro Oncol. 2008;10(4):631-42.

  35. Jaeckle KA, Eyre HJ, Townsend JJ, et al. Correlation of tumor O6 methylguanine- DNA methyltransferase levels with survival of malignant astrocytoma patients treated with bis-chloroethylnitrosourea: a Southwest Oncology Group study. J Clin Oncol. 1998;16(10):3310-5.

  36. Mendez G, Ozpinar A, Raskin J, Gultekin SH, Ross DA. Case comparison and literature review of glioblastoma: A tale of two tumors. Surg Neurol Int. 2014;5:121.

  37. Parkinson JF, Wheeler HR, Clarkson A, McKenzie CA, Biggs MT, Little NS, et al. Variation of O(6)-methylguanine-DNA methyltransferase (MGMT) promoter methylation in serial samples in glioblastoma. J Neuro Oncol. 2008;87(1):71-8.

  38. Akers JC, Ramakrishnan V, Kim R, et al. MiR-21 in the extracellular vesicles (EVs) of cerebrospinal fluid (CSF): a platform for glioblastoma biomarker development. PloS one. 2013;8(10):e78115.

  39. Sugawara H, Iwamoto K, Bundo M, Ueda J, Ishigooka J, Kato T. Comprehensive DNA methylation analysis of human peripheral blood leukocytes and lymphoblastoid cell lines. Epigenetics. 2011;6(4):508-15.

  40. Laxton RC, Popov S, Doey L, et al. Primary glioblastoma with oligodendroglial differentiation has better clinical outcome but no difference in common biological markers compared with other types of glioblastoma. Neuro Oncol. 2013;15(12):1635-43.

  41. Collet B, Guitton N, Saikali S, et al. Differential analysis of glioblastoma multiforme proteome by a 2D-DIGE approach. Proteome Sci. 2011; 9(1):16.

  42. Medina Villaamil V, Alvarez Garcia A, Aparicio Gallego G, et al. Tissue array analysis for the differentiation of gliosis from gliomas. Mol Med Rep. 2011;4(3):451-7.

  43. Yakut T, Gutenberg A, Bekar A, et al. Correlation of chromosomal imbalances by comparative genomic hybridization and expression of EGFR, PTEN, p53, and MIB-1 in diffuse gliomas. Oncol Rep. 2007;17(5): 1037-43.

  44. Demirci U, Yaman M, Buyukberber S, et al. Prognostic importance of markers for inflammation, angiogenesis and apoptosis in high grade glial tumors during temozolomide and radiotherapy. Int Immunopharmacol. 2012;14(4):546-9.

  45. Jha P, Suri V, Jain A, et al. O6-methylguanine DNA methyltransferase gene promoter methylation status in gliomas and its correlation with other molecular alterations: first Indian report with review of challenges for use in customized treatment. Neurosurg. 2010;67(6):1681-91.

  46. Ma YH, Mentlein R, Knerlich F, Kruse ML, Mehdorn HM, Held-Feindt J. Expression of stem cell markers in human astrocytomas of different WHO grades. J Neurooncol. 2008;86(1):31-45.




2020     |     www.medigraphic.com